(Q38109430)

29 August 2017

title

Incidence and management of edema associated with trebananib (AMG 386). (English)

1 reference

29 August 2017

3

Sandrina Lambrechts

0 references

Bradley J. Monk

1

object named as

Bradley J Monk

1 reference

29 August 2017

Lindsey Minion

2

1 reference

29 August 2017

Ignace B Vergote

4

1 reference

29 August 2017

Nele Devoogdt

5

1 reference

29 August 2017

Beth Y Karlan

6

1 reference

29 August 2017

language of work or name

English

0 references

publication date

23 May 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

130

1 reference

29 August 2017

issue

3

1 reference

29 August 2017

page(s)

636-641

1 reference

AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.023

AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, inhibits angiogenesis in models of ocular neovascular diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.023

Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.023

Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.023

Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.023

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.023

What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.023

Incorporation of bevacizumab in the primary treatment of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.023

Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.023

Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.023

Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.023

AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.023

Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.023

A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.023

Angiopoietin-1 promotes lymphatic sprouting and hyperplasia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.023

Targeting the ANGPT-TIE2 pathway in malignancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.05.023

10.1016/J.YGYNO.2013.05.023

7 January 2021

Identifiers

DOI

1 reference

29 August 2017

1 reference